QuidelOrtho — Third Quarter 2026 Earnings Summary

QuidelOrtho reported a 12% decline in third-quarter 2026 total revenue to $619 million, driven by lower sales in China and a softer respiratory season, though underlying business strength was evident with a 2% growth in revenue excluding respiratory, China, and U.S. Donor Screening. The company recorded a GAAP net loss of $54 million and an adjusted EBITDA of $148 million, while announcing a new cost transformation program expected to generate over $80 million in annual savings by 2027. Full-year 2026 financial guidance was updated to reflect total revenues between $2.52 billion and $2.54 billion and adjusted diluted EPS between $0.65 and $0.70.